Impact of *BRCA* mutation status on tumor infiltrating lymphocytes (TILs), response to treatment, and prognosis in breast cancer patients treated with neoadjuvant chemotherapy.

Beatriz Grandal^{1,10}*, Clémence Evrevin¹*, Enora Laas¹, Isabelle Jardin¹, Sonia Rozette¹, Lucie Laot¹, Elise Dumas¹⁰, Florence Coussy², Jean-Yves Pierga², Etienne Brain³, Claire Saule⁴, Dominique Stoppa-Lyonnet⁴, Sophie Frank⁴, Claire Sénéchal⁵, Marick Lae^{6,7}, Diane De Croze⁶, Guillaume Bataillon⁸, Julien Guerin⁹, Fabien Reyal^{1,10**}, Anne-Sophie Hamy^{10**}

* Beatriz Grandal and Clémence Evrevin / ** Fabien Reyal and Anne-Sophie Hamy contributed equally to this work.

Affiliations:

- 1. Department of Surgery, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
- 2. Department of Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
- 3. Department of Oncology, Centre René Huguenin Institut Curie, 35 rue Dailly, 92210 St Cloud, France
- 4. Department of Genetics, Institut Curie, 26 rue d'Ulm, 75005 Paris, France INSERM U830, Institut Curie Paris, Paris, France.
- 5. Department of Genetics, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France
- 6. Department of Pathology, Centre René Huguenin Institut Curie, 35 rue Dailly, 92210 St Cloud, France
- 7. Department of Pathology, Centre Henri Becquerel, INSERM U1245, uniRouen, University of Normandie, Rouen, France
- 8. Department of Pathology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
- 9. Data Office, Institut Curie, 25 rue d'Ulm, 75005 Paris, France
- 10. Residual Tumor & Response to Treatment Laboratory, RT2Lab, translational Research Department, INSERM, U932 Immunity and Cancer, Institut Curie, 26 rue d'Ulm, Paris, France
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Running title:

Impact of *BRCA* mutation status on TILs, pCR and survival in breast cancer patients treated with neoadjuvant chemotherapy.

Keywords:

BRCA, TILs, pCR, NAC, immunotherapy

Financial Support:

B.G.R. was supported by Alfonso Martin Escudero Foundation research grant.

Corresponding author:

Pr. Fabien REYAL

Institut Curie, 26 rue d'Ulm, 75005 Paris, France

+33 144324660/ Fax +33 153104037

fabien.reyal@curie.fr

Conflict of interest

The authors declare no potential conflicts of interest.

Others

Word count: 3152 Total number of figures: 4 Total number tables: 2

Translational relevance

High lymphocytic infiltration (TILs) seem to reflect favorable host antitumor immune responses. In breast cancer, the variation of TILs before and after neoadjuvant chemotherapy (NAC) according to *BRCA* status has been poorly described. Little data is available on their value after treatment. We investigated TIL levels before and after NAC and response to treatment in 267 paired biopsy and surgical specimens.

6 In our study, luminal BCs were associated with pathologic complete response (pCR) and 7 higher TIL levels after chemotherapy completion in patients with *BRCA* pathogenic 8 mutations. Our data supports that (i) NAC should be reconsidered in luminal BCs with *BRCA* 9 pathogenic mutation, (ii) TILs could be a biomarker for response to immune checkpoint 10 blockade in luminal BCs with *BRCA* pathogenic variant who did not achieve a pCR and (iii) 11 exploiting the antitumor immune response in luminal BCs could be an area of active research.

1 Abstract:

Introduction: Five to 10% of breast cancers (BCs) occur in a genetic predisposition context
(mainly BRCA pathogenic variant). Nevertheless, little is known about immune tumor
infiltration, response to neoadjuvant chemotherapy (NAC), pathologic complete response
(pCR) and adverse events according to *BRCA* status.

6 *Material and methods:* Out of 1199 invasive BC patients treated with NAC between 2002 and 7 2012, we identified 267 patients tested for a germline *BRCA* pathogenic variant. We evaluated 8 pre-NAC and post-NAC immune infiltration (TILs). Response to chemotherapy was assessed 9 by pCR rates. Association of clinical and pathological factors with TILs, pCR and survival 10 was assessed by univariate and multivariate analyses.

11 Results: Among 1199 BC patients: 46 were BRCA-deficient and 221 BRCA-proficient or wild 12 type (WT). At NAC completion, pCR was observed in 84/266 (31%) patients and pCR rates 13 were significantly higher in *BRCA*-deficient BC (p = 0.001), and this association remained 14 statistically significant only in the luminal BC subtype (p=0.006). The interaction test 15 between BC subtype and BRCA status was nearly significant (Pinteraction=0.056). Pre and post-16 NAC TILs were not significantly different between BRCA-deficient and BRCA-proficient 17 carriers; however, in the luminal BC group, post-NAC TILs were significantly higher in 18 BRCA-deficient BC. Survival analysis were not different between BRCA-carriers and non-19 carriers.

Conclusion: BRCA mutation status is associated with higher pCR rates and post-NAC TILs in
 patients with luminal BC. *BRCA*-carriers with luminal BCs may represent a subset of patients
 deriving higher benefit from NAC. Second line therapies, including immunotherapy after
 NAC, could be of interest in non-responders to NAC.

1 Introduction

Neoadjuvant or pre-operative chemotherapy (NAC) is classically administered to patients with inflammatory or locally advanced breast cancer (BC). Beyond increasing breastconserving surgery rates (1), it also serves as an *in vivo* chemosensitivity test and the analysis of residual tumor burden may help understanding treatment resistance mechanisms (2). In addition, it helps refining the prognosis of patients after NAC, as pathological complete response (pCR) after NAC is associated with a better long term survival (1,3).

8 Nearly 5% of breast cancers occur in a context of **genetic predisposition**, mostly represented 9 by monoallelic pathogenic variants of BRCA1, BRCA2 or PALB2 genes (4). Patients with 10 loss-of-function of the BRCA1 or 2 proteins have a higher cumulated breast cancer risk, with a cumulated life time risk at eighty years old of 72% (BRCA1) and 69% (BRCA2)(5). The 11 12 peak incidence for BRCA1 mutation carriers occurs between 41 and 50 years old (28.3 per 13 1000 person-years), whereas it occurs ten years later for BRCA2 mutation carriers (30.6 per 14 1000 person-years between 51 and 60) (5). BRCA1 and BRCA2 are tumor-suppressor genes 15 that code for proteins involved in homologous recombination (HR) repair. HR deficiency 16 (HRD) occurs when the second allele is inactivated by allelic deletion (often detected by 17 LOH), genic alteration or promoter methylation (for BRCA1 only). Biallelic BRCA1/2 18 inactivation results in genomic instability and theoretically increases the somatic mutational 19 load (6).

Tumors associated with germline or somatic *BRCA1/2* pathogenic mutations **display different patterns when compared with sporadic BCs**. Cancers occurring among *BRCA1* carriers are more frequently classified as medullary (7), whereas histological subtypes among *BRCA2* carriers tend to be more heterogeneous (8). In addition, *BRCA1* carriers are more frequently ER-negative, PR-negative and lack *HER2* amplification (*i.e.* display a triple

negative (TNBCs) phenotype (9))- whereas in *BRCA2* carriers, a similar prevalence of ERpositive tumors has been described when compared with sporadic controls (10–13).

Most of patients with TNBCs receive **chemotherapy** (14,15). Due to the alteration of BRCA1 and BRCA2 proteins in tumor cells, *BRCA*-mutated cells are unable to properly repair doublestrand breaks, classically induced by DNA-alkylating agents (16). Hence, *BRCA* deficiency has sometimes been associated with a higher sensitivity to platinum agents when compared to other types of neoadjuvant chemotherapy regimens (17–19). However, the effectiveness of standard NAC in all BC subtypes associated with *BRCA* pathogenic variants compared to controls has been poorly explored so far.

10 The role of **tumor infiltrating lymphocytes (TILs)** in BC has been extensively studied over 11 the last decade. High levels of TILs before NAC are associated with higher pCR rates and 12 better survival, especially for TNBC and *HER2*-positive BCs (20,21). However, despite a 13 growing interest in the field of immunity and oncology, characterization and quantification of 14 TILs across all BC subtypes according to *BRCA* status has not been extensively described. 15 Similarly, no study has evaluated so far, the evolution of immune infiltration after NAC 16 according to *BRCA* status.

17 The objective of the current study is to determine if pre and post-NAC TILs, chemosensitivity18 and prognosis differ according to *BRCA* status in a cohort of BC patients treated with NAC.

1 Material and methods:

2 Patients and Tumors

3 The study was performed on a retrospective institutional cohort of 1199 female patients with 4 T1-T3NxM0 invasive BC (NEOREP Cohort, CNIL declaration number 1547270) treated with 5 NAC at Institute Curie (Paris and Saint-Cloud) between 2002 and 2012. The cohort included 6 unifocal, unilateral, non-recurrent, non-metastatic tumors, excluding T4 tumors 7 (inflammatory, chest wall or skin invasion). Approved by the Breast Cancer Study Group of 8 Institute Curie, the study was conducted according to institutional and ethical rules 9 concerning research on tissue specimens and patients. Informed consent from patients was not 10 required.

Information on family history, clinical characteristics (age; menopausal status; body mass index) and tumor characteristics (clinical tumor stage and grade; histology; clinical nodal status; ER, PR and *HER2* status; BC subtype; mitotic index; Ki67) were retrieved from electronic medical records. All the patients received NAC, and additional treatments were decided according to national guidelines (see **Supplementary material**).

16

17 **Tumors samples**

In accordance with French national guidelines (22), cases were considered estrogen receptor (ER)-positive or progesterone receptor (PR)-positive if at least 10% of tumor cells expressed estrogen and/or progesterone receptors (ER/PR), and endocrine therapy was prescribed when this threshold was exceeded. *HER2* negative status was defined as 0 or 1 + on immunohistochemistry (IHC) stained tissue section. IHC 2 + scores were subsequently analyzed by fluorescence *in situ* hybridization (FISH) to confirm *HER2* positivity.

Pathological BC were classified into subtypes (TNBC, *HER2*-positive, and luminal *HER2* negative [referred to hereafter as "luminal"]) (see Supplementary material).

3

4 TIL levels, pathological complete response and pathological review:

5 TIL levels were evaluated retrospectively for research purposes, by two pathologists (ML and 6 DdC) specialized in breast cancer. TIL levels were assessed on formalin-fixed paraffin-7 embedded (FFPE) tumor tissue samples from pretreatment core needle biopsies and the 8 corresponding post-NAC surgical specimens, according to the recommendations of the 9 international TILs Working Group before (23) and after NAC (24). TILs were defined as the 10 presence of a mononuclear cell infiltrate (including lymphocytes and plasma cells, excluding polymorphonuclear leukocytes). TILs in direct contact with tumor cells were counted as intra-11 12 tumoral TILs (IT TILs) and those in the peri-tumoral areas as stromal TILs (str TILs). They 13 were evaluated both in the stroma and within tumor scar border, after excluding areas around 14 ductal carcinoma in situ, tumor zones with necrosis and artifacts, and were scored 15 continuously as the average percentage of stroma area occupied by mononuclear cells.

We defined pathological complete response (pCR) as the absence of invasive residual tumorfrom both the breast and axillary nodes (ypT0/is N0).

18

19 BRCA status

Genetic counseling was offered based on individual or family criteria (see Supplemental
material). When constitutional genetic analysis of *BRCA1* and *BRCA2* genes were required,
Denaturing High Performance Liquid Chromatography (DHPLC) and Sanger sequencing
were performed to search for point alterations, and Quantitative Multiplex Polymerase Chain
Reaction of Short Fluorescent (QMPSF) to research large gene rearrangements between 2002

and 2012. In case of previously known pathogenic familial variants, targeted tests were
 performed.

3

4 Survival endpoints

Relapse-free survival (RFS) was defined as the time from surgery to death, loco-regional
recurrence or distant recurrence, whichever occurred first. Overall survival (OS) was defined
as the time from surgery to death. For patients for whom none of these events were recorded,
data was censored at the time of last known contact. Survival cutoff date analysis was
February 1st, 2019.

10

11 Statistical analysis

12 Pre- and post-NAC TIL levels were analyzed as continuous variables. All analyses were 13 performed on the whole population and after stratification by BC subtype. To compare 14 continuous variables among different groups, Wilcoxon-Mann-Whitney test was used for 15 groups including less than 30 patients and for variables displaying multimodal distributions; 16 otherwise, student t-test was used. Association between categorical variables was assessed 17 with chi-square test, or with the Fisher's exact test if at least one category included less than 18 three patients. In boxplots, lower and upper bars represented the first and third quartile 19 respectively, the medium bar was the median, and whiskers extended to 1.5 times the inter-20 quartile range. Factors predictive of pCR were introduced in a univariate logistic regression 21 model. Covariates selected for multivariate analysis were those with a *p*-value no greater than 22 0.1 after univariate analysis. Survival probabilities were estimated by Kaplan-Meyer method, 23 and survival curves were compared with log-rank tests. Hazard ratios (HR) and their 95% 24 confidence intervals (CI) were calculated with the Cox proportional hazard model. Analyses 25 were performed with R software version 3.1.2. Significance threshold was of 5%.

1 Results

2 Study population and tumors characteristics

The total number of patients included in the neoadjuvant cohort was 1199. Among the whole population, germline *BRCA* pathogenic variant status was available for 267 patients (22.3%), and was not obtained for 932 patients (77.73%, **Supplementary Figs. S1**). Median age of cohort's population was 48 years old (range 24-80) and most patients (n=747, 62%) were premenopausal. Median BMI index was 24.74, and 25.8% had direct family history of breast cancer. Patients repartition by subtype was as follows: luminal (n=518, 44%), TNBC (n= 376, 31%), *HER2*-positive (n= 295, 25%).

Patients with available *BRCA* status were significantly different from patients with *BRCA* status unknown. They were younger, had lower body mass index, were more likely to be diagnosed with grade III, TNBC of no specific type (NST), and to receive standard anthracyclines-taxanes containing regimens than patients not screened (p< 0.001) (**Table1**, **Supplementary Figs. S2**).

Among the 267 screened patients, the distribution of *BRCA* status was as follows: *BRCA*proficient n=221 (83%); *BRCA*-deficient, n= 46 (17%) (*BRCA1*-deficient, n=31 (67.39%); *BRCA2*-deficient, n = 14 (30.43%) and *BRCA1*+2-deficient, n=1 (2.17%)). Median age at diagnosis for patient with available *BRCA* mutation status was 40 years old (range 24-70) and most patients (n=227, 85%) were premenopausal. Patients repartition by subtype was as follows: luminal (n=90, 33.7%), TNBC (n= 110, 41.2%), *HER2*-positive (n= 67, 25.1%) (**Supplementary Table S1, Supplementary Fig. S2**).

Carriers of a *BRCA* pathogenic variant were more likely to have familial history of breast cancer (73.9% vs. 52.3%, p= 0.012), and to be diagnosed with TNBC (58.7% vs 37.6%; p=

0.006) than *BRCA*-proficient patients (**Table 1**). No other pattern among age, body mass
 index, histology, tumor size, nor proliferation indices (grade, mitotic index, KI67) was
 significantly different according to *BRCA* variant status. These results were substantially
 similar after the subgroup analysis of BC subtype (**Supplementary Table S2**).

			BRCA	BRCA wild-	Not screened		
Characteristics	Class		mutation	type		р	
n=		1199(100%)	46(3.8%)	221(18.4%)	932(77.7%)		
Age (mean)		48.6	39.5	41.7	50.6	<0.01	
Menopausal	pre	747 (62.8)	41 (89.1%)	187 (85.0%)	519 (56.2%)	<0.01	
status	post	442 (37.2)	5 (10.9%)	33 (15.0%)	404 (43.8%)		
BMI (mean)		24.7	22.8	23.6	25.1	<0.01	
BMI class	[15,19]	72 (6.0)	6 (13.3)	17 (7.7)	49 (5.3)	<0.01	
	(19,25]	664 (55.7)	31 (68.9)	147 (66.5)	486 (52.4)		
	(25,30]	299 (25.1)	4 (8.9)	43 (19.5)	252 (27.2)		
	(30,50]	158 (13.2)	4 (8.9)	14 (6.3)	140 (15.1)		
Family history	no	887 (74.2)	12 (26.1%)	104 (47.7%)	771 (82.7%)	<0.01	
of BC	yes	309 (25.8)	34 (73.9%)	114 (52.3%)	161 (17.3%)		
Clinical tumor size	T1	70 (5.8%)	5 (10.9%)	22 (10.0%)	43 (4.6%)	<0.01	
	T2	798 (66.6%)	28 (60.9%)	153 (69.2%)	617 (66.3%)		
	Т3	330 (27.5%)	13 (28.3%)	46 (20.8%)	271 (29.1%)		
Clinical	NO	525 (43.8%)	17 (37.0%)	93 (42.1%)	415 (44.6%)	0.51	
nodal status	N1-N2-N3	673 (56.2%)	29 (63.1%)	128 (57.9%)	516 (55.4%)		
Histology	NST	1062 (90%)	43 (93.5%)	213 (96.4%)	806 (88.3%)	0.03	
	others	118 (10%)	3 (6.5%)	8 (3.6%)	108 (11.6%)		
Grade	1-11	479 (41.4%)	10 (23.3%)	76 (34.7%)	393 (43.9%)	0.01	
	Ш	678 (58.6%)	33 (76.7%)	143 (65.3%)	502 (56.1%)		
Mitotic Index (mea	n)	25.1	30.8	25.6	24.6	0.25	
Subtype	luminal	528 (44.0%)	15 (32.6%)	75 (33.9%)	438 (47.0%)	<0.01	
	TNBC	376 (31.4%)	27 (58.7%)	83 (37.6%)	266 (28.5%)		
	HER2	295 (24.6%)	4 (8.7%)	63 (28.5%)	228 (24.5%)		
str Til s (moon)		20.0 [10.0-	20.0 [13.8-	20.0 [10.0-	15.0 [10.0-	0.02	
str TILS (mean)		30.0]	40.0]	40.0]	30.0]	0.02	
IT TILs (mean)		5.0 [5.0-15.0]	5.0 [5.0-11.2]	7.5 [5.0-20.0]	5.0 [3.0-15.0]	0,47	
NAC Regimen	AC	235 (19.6%)	4 (8.7%)	25 (11.4%)	206 (22.2%)	<0.01	
	AC-Taxanes	845 (70.7%)	41 (89.1%)	180 (81.8%)	624 (67.1%)		
	Taxanes	25 (2.1%)	1 (2.2%)	6 (2.7%)	18 (1.9%)		
	Others	91 (7.6%)	0 (0.0%)	9 (4.1%)	82 (8.8%)		
pCR class	No pCR	911 (76.2)	25 (54.3)	157 (71.4)	729 (78.4)	<0.001	
	pCR	285 (23.8)	21 (45.7)	63 (28.6)	201 (21.6)		
Nodal involvment	0	682 (57.0)	35 (76.1)	141 (64.1)	506 (54.4)	0.003	
	1-3	341 (28.5)	6 (13.0)	58 (26.4)	277 (29.8)		
	≥4	174 (14.5)	5 (10.9)	21 (9.5)	148 (15.9)		
str TILs (mean)		10.0 [5.0-15.0]	15.0 [5.0-20.0]	10.0 [5.0-15.0]	10.0 [5.0-15.0]	0.36	
IT TILs (mean)		5.0 [2.0-10.0]	5.0 [4.3-10.0]	5.0 [2.0-10.0]	5.0 [2.0-10.0]	0.57	
Missina data · Men	onausal status n="	10: BMI (continue	ous) n=6: BMI cl	ass n=6. Family	history n=3. Clin	ical tumor	

Table1. Patients' characteristics among the whole population

stage, n=1; Clinical nodal status, n=1; Histology, n=19; Grade, n=42; Mitotic index, n=502; Pre-NAC str TILs, n=482; Pre-NAC IT TILs, n=482; NAC regimen, n=3; pCR status, n=3; Post-NAC Nodal involvment, n=2; Post-NAC str TILs, n=482; Post-NAC IT TILS, n=714.

Abbreviations: NAC=neoadjuvant chemotherapy ; BMI=body mass index; NST= no special type; TNBC= triple negative breast cancer ; str TILs= stromal tumor-infiltrating lymphocytes ; IT TILs= intratumoral-infiltrating lymphocytes; AC=anthracyclines; pCR=Pathologic complete response.

The "n" denotes the number of patients. In case of categorical variables, percentages are expressed between brackets. In case of continuous variables, mean value is reported. In case of nonnormal continuous variables, median value is reported, with interquartile range between brackets.

1

2 Baseline TILs were available for 192 out of 267 screened patients (72%). Neither pre-NAC 3 str TIL levels (Figs 1A-D), nor IT TILs (Figs 1E-H) were significantly different by BRCA 4 status (Supplementary Table S1), nor in each BC subtype (Supplementary Table S2).

1 There was a strong, positive, linear relationship between stromal and intra-tumoral TILs

2 (Spearman correlation coefficient of 0.74, *p*< 0.001, **Supplementary Fig. S3**)



3

17

Figure 1. Associations between pre-NAC TILs and *BRCA* status in whole population, and by breast cancer subtype. Bottom and top bars of the boxplots represent the first and third quartiles, respectively, the medium bar is the median, and whiskers extend to 1.5 times the interquartile range. A, stromal lymphocytes among the whole population (All(n=192), *BRCA* mutation (n=36), *BRCA* wild-type(n=156). B, stromal lymphocytes in each BC subtype (Luminal(n=52), *BRCA* mutation(n=8), *BRCA* wild-type(n=44); TNBC(n=97), *BRCA* mutation(n=24), *BRCA* wild-type(n=73); *HER2*(n=43),*BRCA* mutation(n=4), *BRCA* wild-type(n=39). C, percentage of tumor according to pre-NAC stromal lymphocytes levels binned by 10% increment in patients with *BRCA*-deficient (*BRCA1* (n=24), *BRCA2*(n=12)). D, distribution of pre-NAC stromal lymphocytes among the whole population (All(n=192), *BRCA* wild-type(n=156)). F, intratumoral lymphocytes among the whole population (All(n=192), *BRCA* mutation (n=36), *BRCA* wild-type(n=156)). F, intratumoral lymphocytes in each BC subtype (Luminal(n=52), *BRCA* mutation(n=8), *BRCA* wild-type(n=77); *BRCA* mutation(n=73); *HER2*(n=43),*BRCA* wild-type(n=39)). G, Percentage of tumor according to pre-NAC wild-type(n=73); *HER2*(n=43),*BRCA* wild-type(n=39)). G, Percentage of tumor according to pre-NAC intratumoral lymphocytes levels binned by 10% increment in patients with *BRCA*-deficient (*BRCA1* (n=24), *BRCA* wild-type(n=73); *HER2*(n=43),*BRCA* wild-type(n=39)). G, Percentage of tumor according to pre-NAC intratumoral lymphocytes levels binned by 10% increment in patients with *BRCA*-deficient (*BRCA1* (n=24), *BRCA2*(n=12)).
 HER2(n=43),*BRCA* mutation(n=4), *BRCA*-deficient (*BRCA1* (n=24), *BRCA* (n=124), *BRCA2*(n=12)).

18 **Response to treatment and post-NAC immune infiltration**

19 *Response to treatment*

20 At NAC completion, pCR was observed in 84 out of 266 (31%) patients and pCR rates were

- significantly different by BC subtype (luminal: 10% (9/89), TNBC: 45% (49/110) and HER2-
- 22 positive 39% (26/67), p < 0.001). Pre-NAC str TIL levels were significantly higher in tumors
- for which pCR was achieved (p < 0.001) and there was a significant association between pre-
- NAC TIL levels and pCR status in the whole population (all: OR = 1.03, CI95% [1.02 1.05

], p< 0.001; Supplementary Fig. S3) and in the TNBC subgroup (luminal: OR = 1.03, CI95%
 [1 - 1.09], p= 0.21; TNBC: OR = 1.03; CI95% [1-1.04], p= 0.007; HER2-positive: OR =
 1.02, CI95% [0.99–1.06], p= 0.23; Supplementary Fig. S4).

4 pCR rates were significantly higher in patients with *BRCA*-deficient breast cancers (45.7% 5 (21/46) versus 28 % (63/221) in *BRCA*-proficient, p < 0.035, **Supplementary Table S1**, 6 **Figure 2**). After the subgroup analysis of BC subtype, this was confirmed only in the luminal 7 BC subtype (33.3% (5/15), p = 0.006), but not in TNBC and *HER2*-positive BCs (48.1% 8 (13/27), p = 0.823 and 75% (3/4), p = 0.291, respectively, **Supplementary Table S2**, **Figure** 9 **2**). The interaction test between BC subtype and *BRCA* status was nearly significant 10 ($P_{interaction}=0.056$).





17 and only BC subtype (TNBC, OR = 7.14, CI95% [3.39 - 16.57], p < 0.001; *HER2*-positive,

18 OR = 5.64, CI95% [2.5 - 13.78], =<0.001), tumor size (T2, OR = 0.37, CI95% [0.16 - 0.83

19], p = 0.017; T3, OR = 0.21, CI95% [0.08 - 0.55], p = 0.002) and pre-NAC str and IT TILs

BC patients with pCR rates treated with NAC [(n=266); Luminal (n= 89), TNBC (n= 110), HER2-positive (n= 67)]

Figure 2. Barplot of associations between response to treatment and *BRCA* status in whole population, and by breast cancer subtype. A, among the whole population (All(n=266), *BRCA* mutation (n=46), *BRCA* wild-type(n=220)). B, by BC subtype (Luminal(n=89), *BRCA* mutation(n=15), *BRCA* wild-type(n=74); TNBC(n=110), *BRCA* mutation(n=27), *BRCA* wild-type(n=83); *HER2*(n=67),*BRCA* mutation(n=4), *BRCA* wild-type(n=63)).

¹⁶ However, BRCA status was not significantly associated with pCR after multivariate analysis,

- 1 (OR = 1.03, CI95% [1.02 - 1.05], p = 0.001 and OR = 1.04, CI95% [1.02 - 1.07], p = 0.002)
- 2 were independent predictors of pCR (Supplementary Table S3).

3 Post-NAC Immune Infiltration by BRCA status



56 78 910 11 12 13 14 15 16 17 Figure 3. Associations between post-NAC TILs and BRCA status in whole population, and after stratification by breast cancer subtype. Bottom and top bars of the boxplots represent the first and third quartiles, respectively, the medium bar is the median, and whiskers extend to 1.5 times the interquartile range. A, stromal lymphocytes among the whole population (All(n=192), BRCA mutation (n=36), BRCA wild-type(n=156)). B, stromal lymphocytes in each BC subtype (Luminal(n=52), BRCA mutation(n=8), BRCA wild-type(n=44); TNBC(n=97), BRCA mutation(n=24), BRCA wild-type(n=73); HER2(n=43), BRCA mutation(n=4), BRCA wild-type(n=39)). C, Percentage of tumor according to post-NAC stromal lymphocytes levels binned by 10% increment in patients with BRCA-deficient (BRCA1 (n=24), BRCA2(n=12)). D, distribution of post-NAC stromal lymphocytes by gene mutations (histogram plot) in patients with BRCA-deficient (BRCA1(n=24), BRCA2(n=12)). E, intratumoral lymphocytes among the whole population (All(n=120), BRCA mutation (n=20), BRCA wild type(n=100)). F, intratumoral lymphocytes in each BC subtype (Luminal(n=44), BRCA mutation(n=7), BRCA wild-type(n=37); TNBC(n=50), BRCA mutation(n=12), BRCA wild-type(n=38); HER2(n=26), BRCA mutation(n=1), BRCA wild-type(n=25)). G, percentage of tumor according to post-NAC intratumoral lymphocytes levels binned by 10% increment in patients with BRCA-deficient (BRCA1 (n=13), BRCA2(n=7)). H, distribution of pre-NAC intratumoral lymphocytes by gene mutations (histogram plot) in patients with BRCA-deficient (BRCA1 (n=13), BRCA2(n=7)).

BRCA pathogenic mutations when compared with wild-type tumors in luminal BCs (median
 str TIL levels: 15% vs. 10%, p= 0.009 and median IT TIL levels : 10% vs. 5%, p= 0.019,
 respectively, Supplementary Table S2, Figure 3).

Median pre-NAC str TIL were higher than after NAC (20% vs 10%, 11.95%), also according
to *BRCA* status and type (Supplementary Table S1, Fig. 4). There was no correlation
between pre and post NAC str TILs (correlation coefficient of 0.13 and *p*< 0.06,
Supplementary Fig. S5A) and there was a weak, positive, linear relationship between pre
and post NAC IT TIL levels (correlation coefficient of 0.31 and *p*< 0.001, Supplementary
Fig. S5B).

10 Survival analysis

After a median of follow-up of 90.4 months (range from 0.2 to 187 months), 73 patients experienced relapse, and 38 died. RFS and OS were not significantly different between carriers of a *BRCA* pathogenic variant and *BRCA*-proficient patients, neither were they in screened population nor after the subgroup analysis of BC subtype (**Supplementary Figs. S6**-**7**).





1

BC patients with pre and post-NAC str TIL levels available [n=192; BRCA mutation (n= 36), BRCA wild type (n= 156), BRCA1 (n=24), BRCA2 (n=12)]

Figure 4. Pre-NAC and post-NAC stromal immune infiltration rates in the whole population and by BRCA status. A-E, bar plots of str TIL levels before and after NAC in the whole population and in BRCA pathogenic variant. Bottom and top bars of the boxplots represent the first and third quartiles, respectively, the medium bar is the median, and whiskers extend to 1.5 times the interquartile range. (All(n=192); BRCA mutation (n=36), BRCA wild-type(n=156); BRCA1(n=24), BRCA2(12)). F, variation of str TIL levels according to the pre-NAC str TIL levels binned by BRCA status and response to chemotherapy. Points represent the difference between pre- and post-NAC paired TIL levels values of a given patient and are colored according to TIL variation category (TIL level decrease: yellow/no change: green/increase: red) (All(n=191), BRCA mutation (n=36), BRCA wild-type(n=155)). G-D, waterfall plot representing the variation of TIL levels according to BRCAdeficient (BRCA1-deficient, BRCA2-deficient); each bar represents one sample, and samples are ranked by increasing order of TIL level change. Paired samples for which no change was observed have been removed from the graph. (All(n=191), BRCA mutation [(n=36), BRCA1, n= 24; BRCA2= 12)], BRCA wild-type(n=155)).

1 Discussion

In the current study, we did not identify any association between *BRCA* status and immune infiltration whatever the type of TILs (IT, str). We found a better response to neoadjuvant chemotherapy in tumors associated with a germline *BRCA* pathogenic variant when compared to *BRCA*-WT, but the latter was limited to the group of luminal BCs and was not statistically significant after multivariate analysis. Probably in relation, we recovered higher post-NAC lymphocyte infiltration in *BRCA*-deficient tumors in the luminal BC subgroup.

8 Regarding pre-treatment immune infiltration, Sønderstrup and colleagues (25) analyzed str 9 TIL levels in a nationwide cohort of BRCA1 and BRCA2 carriers with primary BCs. They 10 found a greater prevalence of high stromal TILs (defined as TILs-positive tumors with $\geq 60\%$ 11 str TILs) in BRCA1-deficient tumors (n=243) when compared with BRCA2-deficient tumors 12 (n=168) (36% versus 15 % respectively, p < 0.0001). However, no control group with BRCA-WT tumors was available in this study. In a small study of 85 TNBC patients, Solinas and 13 14 colleagues (26) investigated the distribution of TILs subpopulations. The tumors of patients in 15 the *BRCA1* or *BRCA2*-mutated group displayed a higher prevalence of TILs-positive tumors 16 (defined as tumors with $\geq 10\%$ str or IT TILs) when compared with the *BRCA*-WT (93.2%) 17 versus 75.6% respectively, p=0.037). No other statistically significant differences were 18 identified between BRCA-carriers and non-carriers, neither in TILs subpopulations nor their 19 location. More recently, Telli and colleagues (27) investigated the association between TILs, 20 homologous recombination deficiency (HDR) and BRCA1/2 status in a cohort of 161 TNBC 21 patients pooled from 5 phase II neoadjuvant clinical trials of platinum-based therapy. They 22 found that IT TILs and str TILs density were not associated with BRCA1/2 status (p=0.312) 23 and p = 0.391, respectively). Consistently with Telli *et al*, we did not observe any difference in baseline immune infiltration according to BRCA status. 24

1 Some retrospective studies suggested that tumors displayed higher chemosensitivity 2 according to BRCA-mutation status (17-19, 28-35). Arun et al. (31) compared pCR rates after 3 NAC between BRCA1 or BRCA2-carriers (n=57 and n=23, respectively) and WT controls 4 (n=237). The majority of patients (82%) received an anthracycline-taxane containing regimen 5 as NAC. The authors found that *BRCA1* mutation was an independent positive predictor of 6 pCR (OR=3.16, 95%CI 1.55-6.42, p = 0.002). In the largest study so far, Wunderle *et al.*(18) 7 investigated efficacy of chemotherapy among a cohort of 355 patients composed with 16.6% 8 (59/355) of BRCA-carriers. Across all BC subtypes, 64.4% of patients with a BRCA1/2 9 pathogenic variant received anthracycline-based treatments, while the rest received 10 carboplatin. pCR was observed in 54.3% (32/59) of all BRCA1/2 mutation carriers, and in 11 39.5% (15/34) of the BRCA-carriers versus 13% of the WT BCs in the anthracycline-regimen. 12 In our cohort, we found similar results after univariate analysis, and we additionally 13 evidenced a nearly significant interaction with BC subtype. The fact that our results were no 14 longer significant after multivariate analysis is possibly due to a lack of statistical power.

15 Furthermore, we found that both str and IT TIL levels were higher after NAC completion in 16 the luminal BCs. Whether this difference in post treatment TILs is a cause, a consequence, or 17 unrelated to response to chemotherapy remains unknown. Indeed, post-NAC TIL levels have 18 been shown to be strongly related to response to chemotherapy in BC cohorts including all 19 BC subtypes (36–38) but only a few studies have investigated the dynamic of TIL levels in 20 response to NAC. Hamy *et al.*(38) noticed that mean TIL levels decreased after chemotherapy 21 completion across all the BC subtype (pre-NAC TILs: 24.1% vs. post-NAC TILs: 13.0%, p <22 0.001). This decrease was strongly associated with high pCR rates, and the variation of TIL 23 levels was strongly inversely correlated with pre-NAC TIL levels (and the variation of TIL 24 levels was strongly inversely correlated with pre-NAC TIL levels (r= - 0.80, p < 0.001).

Finally, in line with several recently published clinical studies (39–41), we found that survival outcomes were not different between *BRCA*-carriers and non-carriers. A multivariate study, including 223 BC patients carrying *BRCA* pathogenic variants and 446 controls with sporadic BC matched for age and year of diagnosis, showed no difference in terms of specific BC survival between *BRCA1* or *BRCA2* mutation carriers and controls (42). Templeton et *al.* evaluated a total of 16 studies comprising data from 10,180 patients and concluded that *BRCA* pathogenic mutations were not associated with a worse overall survival (43).

8 Limits of our study include its retrospective design as well as small effectives potentially 9 leading to a lack of statistical power. Moreover the incidence of bi-allelic pathogenic 10 alterations in HR-related genes according to somatic origin is well-known and ranches from 1 11 to 2 % (44) but we did not explore somatic mutational status in the tumor tissues in the 12 current study.

It also has several strengths, for instance by being the largest cohort with a *BRCA*-WT control
group, and analyses performed after stratification by BC subtype. Finally, to our knowledge,
we provide data on post-NAC immune infiltration according to *BRCA* status for the first time.

16 Our study has several implications. First, it generates an unprecedented hypothesis that 17 luminal BC patients with germline BRCA pathogenic variants may represent a subset of 18 luminal BCs that are more likely to benefit from chemotherapy as primary treatment than the 19 whole luminal BC population. It is known that the absolute benefit of chemotherapy is lower 20 in luminal BC than in the other BC subtypes (45). If further validated in independent cohorts, 21 our findings might lead to reconsider standard use of chemotherapy in patients with luminal 22 BC associated with BRCA pathogenic mutations. Second, patients not achieving pCR may be 23 candidates for post-operative clinical trials exploring alternative therapeutic strategies. As 24 post-NAC immune infiltration seems to be higher in post-NAC specimens of luminal tumors

with *BRCA* pathogenic mutations, we can hypothesize that those tumors would be more likely
to respond to checkpoint inhibitors after chemotherapy. Second line trials using immune
checkpoint inhibitors (such as anti–PD-1 and anti–PD-L1 antibodies) alone or in combination,
together with endocrine therapy could be a relevant strategy for patients failing to reach pCR
at NAC completion.

 Table 2. Literature Review. Abbreviations, CMF=cisplatine- methotrexate- fluorouracile ; AT=docetaxel-doxorubicine ; AC=doxorubicine-cyclophosphamide ; FAC=fluorouracile-doxorubicin-cyclophophosphamide ;

 CEF=cyclophosphamide-epirubicine-fluorouracile ; A=anthracycline ; Dx=doxorubicine ; Do=docetaxel ; Cb=carboplatin ; Cis=cisplatine ; BEV=bevacizumab ; PTX=paclitaxel ; T=taxane.

Study	Setting /Design	Control group	Number of patient (n)	TNBC (n)	HER2- positive (n)	Luminal (n)	BRCA1	BRCA2	BRCA 1 and 2	Chemotherapy regimen *	sTILS evaluation	pCR in BRCA- carriers vs non-carriers	survival analyses	Comments
Chappuis (2002) Journal of Medical Genetics	Neoadjuvant Retrospective multicentric clinical trial	Yes	38	NA	NA	NA	7	4	0	FAC AC CEF AC+ CMF AC + Do	No	44% vs 4%	No	pCR was achieved in 44% (4/11) of the BRCA-carriers and 4%(1/27) of the non-carriers (p=0.009). No survival analysis were experienced in this study.
Byrski (2009) JCO	Neoadjuvant Epidemiologic retrospective cohort (nationwide)	No	102	NA	6	NA	102	0	0	CMF; AT; AC FAC or Cis	No	23.5%	No	pCR was achieved in 23.5% of 102 patients with a BRCA1 mutation who received NAC. Especially, a complete pCR was observed in 8% (2/25) with AT- regimen (standard of care) compared to 83% (10/12) with cisplatin.
Arun (2011) JCO	Neoadjuvant Epidemiologic retrospective cohort	Yes	317	77	60	NA	57	23	0	A-single agent; AT or T-single-agent	No	46% vs 22%	Yes	pCR was achieved in 46% of BRCA1-carriers and 13% of BRCA2-carriers and 22% of BRCA non-carriers (<0.001). In the multivariate logistic model, BRCA1 status (OR=1.96, p=.03) remained as independant significant predictors of a pCR. No significant difference in overall prognosis.
Wang (2014) Annals of Oncology	Neoadjuvant Epidemiologic retrospective cohort	Yes	652	652	0	0	52	NA	0	A-single agent; AT or T-single-agent	No	53.8% vs 29.7%	Yes	The pCR rate was 31,6% in the 652 patients who received NAC. BRCA1 carriers had a significantly higher pCR rate than non-carriers (BRCA1 carriers versus non-carriers, 53.8% versus 29.7%, P < 0.001), Among women treated with anthracycline with or without taxane regimens, the pCR rate was 57.1% for BRCA1 carriers, 29.0% for non-carriers (P < 0.001). The RFS was similar between BRCA1 carriers and non-carriers.
Byrski (2014) BCRT	Neoadjuvant Epidemiologic prospective cohort	No	10	10	0	0	10	0	0	Cis	No	90%	No	90% (9/10) in BRC41-mutated BC patients achieved a pCR after NAC with cisplatin chemotherapy.
Byrski (2015) HCCP	Neoadjuvant Epidemiologic prospective cohort	No	107	82	2	NA	107	0	0	Cis	No	61%	No	61% (65/107) in BRCA1-mutated BC patients achieved pCR after NAC with cisplatin chemotherapy. In this study of BRCA1-mutation carriers, a pCR was also achieved in 56% of 16 patients with ER-positive BC. No survival analysis were experienced in the current study.
Paluch-Shimon (2016) BCRT	Neoadjuvant Epidemiologic retrospective cohort	Yes	80	80	0	0	34	0	0	AT	No	68% vs 37%	Yes	The BRCA1 carriers had pCR rate of 68 % compared with 37 % among non-carriers, p = 0.01. Yet this did not translate into superior survival for BRCA1 carriers compared with non-carriers.
Bignon (2017) Breast	Neoadjuvant Epidemiologic retrospective cohort	No	53	53	0	0	46	6	1	A-single agent or AT	No	66%	Yes	The pCR rate was 38.3% [95% CI, 26%-55%] among BRCA1 mutation carriers, and 66% among the 6 BRCA2 mutation carriers. 15 relapses and 6 second cancers were recorded during the follow-up period. 11 deaths occurred, all of which were in the non-pCR group. DFS (P < .01) and OS (P < .01) were significantly better in the pCR group than the non-pCR group.
Hanhnen (2017) JAMA oncology	Neoadjuvant secondary analysis of the GeparSixto randomized clinical Trial	Yes	291	291	0	0	50	<u></u>	0	AT + BEV +/- Cis	No	66.7 % vs 36.4%	Yes	Patients with BRCA-mutation did not derive a pCR benefit from the addition of cathoptatine (65.4% v 66.7%) compared to non-BRCA carriers (55% v 36.4%). No significant difference in overall prognosis observed in the BRCA-mutated subgroup.
Sharma (2017) CCR	Neoadjuvant prospective, multicenter, non-randomized trial	Yes	190	190	0	0	30		0	Cb + Do	No	59% vs 56%	No	No significative difference in pCR between BRCA-carriers and WT TNBC (59% and 56%, respectively (p=0.83)). The Carboplatin- Docetaxel regimen was well tolerated and yielded high pCR rates in both BRCA associated and WT TNBC. These results are comparable to pCR of previous studies (who investigated pCR after NAC with addition of carboplatin to anthracycline-taxane chemotherapy in TNBC cohort).
Wunderle (2018) BCRT	Neoadjuvant Epidemiologic retrospective cohort	Yes	355	138	58	159	43	16	0	AT ; Cb	No	54.3% vs 12.6%	Yes	pCR was observed in 54.3% of BRCA1/2 mutation carriers, but only in 12.6% of non-carriers. The adjusted odds ratio was 2.48 (95% Cl 1.26–4.91) for BRCA1/2 carriers versus non-carriers. No difference in overall survival was observed.
Saether (2018) HCCP	Neoadjuvant Epidemiologic retrospective cohort	No	12	NA	NA	NA	12	0	0	Cis + Dx or Cb + Do	No	83%	No	11 patients received a combination of cisplatin and doxorubicin, and 1 patient received carboplatin and docetaxel. 83% (10/12) of the BRCA1-carriers results were comparable to existing results found in similar pCR. This results were comparable to existing results found in similar studies. No information about BC subtype among the study population and the toxicity of the chemotherapy was not evaluated.
Sella (2018) Breast	Neoadjuvant Epidemiologic retrospective cohort	Yes	43	43	0	0	14	0	0	AT +/- Cb	No	67% vs 38%	No	pCR was achieved in 38% in BRCA WT compared to 67% in BRCA-associated TNBC (p = 0.232). No benefit from the addition of carboplatine in BRCA-carriers (64.3% v 67%) compared to non-BRCA carriers (44.8% v 38%) when compared to historic institutional rates with AT.
Telli (2019) CCR	5 pooled analyses of phase II	Yes	161	161	0	0	34	L	0	Cb + gemcitabine + Iniparib ; Cis ; Cis + BEV ; Cb + Eribulin ; Cb + nab-PTX +/- Vorinostat	Yes	No	No	pCR was achieved in 51 (61.7%) patients. In patients with TNBC readed with neoadjuvant platinum-based therapy. ITL and sTIL densities were not significantly associated with RECAT2-mutated turnor status (con 312 and p = 0.312 and p = 0.312 and p = 0.312 and p = 0.311 and status (CR 1.62, 95% CI density (CR 1.23, 95% CI 0.94-1.61, p=0.139) was not associated with pCR, but was associated with RCB 01 status (CR 1.62, 95% CI 1.20-2.28, p=0.001).
Solinas (2019) Cancer Letters	Epidemiologic retrospective cohort	Yes	85	85	0	0	38	6	0	NA	Yes	No	Yes	The BRCA-mutated tumors had a significantly higher incidence of TIL-positive levels compared to WT (44% and 41%, respectively $p = 0.037$). No significant difference between BRCA-mutated and WT groups neither in TIL subpopulation nor their location. No difference in in IDFS and OS after stratification on TIL infiltration levels.
Sønderstrup (2019) Acta Oncologica	Epidemiologic prospective mulitcentric cohort (nationwide)	No	411	NA	24	NA	243	168	0	NA	Yes	No	Yes	High sTLs(defined as TLs-560%) were observed in 36% in 2RCA1* and 15% in 2RCA2*nutated tumors (p-c0.0001). Significant association with survival (OS and DFS) was observed in BRCA1 subgroup. sTLs are an important prognostic factor in BRCA BC and increasing sTLs is associated with a better prognosis.
Our study (2020)	Epidemiologic prospective cohort	Yes	267	110	67	90	31	14	1	A-single agent; AT or T-single-agent	Yes	45.7% vs 28.6%	Yes	Among the whole population, 84 tumors achieved a pCR (31.5%). After stratification by BC subtype, pCR rates were significantly higher in turninal BRCA-mutated BCs when compared with WT tumors (33.3% vs 54%, p=0.000, Pre and post-NAC str ort TTLs were not significantly different between BRCA-entraires and non-carriers in whole population. In the functional BC, both str and IT post-NAC TIL levels were significantly higher in BRCA-mutated tumors when compared with WT tumors but was no longer significant after mutilivariate analysis. No difference in RFS or OS between BRCA-mutated and BRCA-WT patients.

1 **References:**

- Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al.
 Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel
 Project Protocols B-18 and B-27. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:778–
 85.
- Reyal F, Hamy AS, Piccart MJ. Neoadjuvant treatment: the future of patients with breast cancer. ESMO Open. 2018;3:e000371.
- Luangdilok S, Samarnthai N, Korphaisarn K. Association between Pathological Complete
 Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced
 Breast Cancer Patients. J Breast Cancer. 2014;17:376–85.
- Huang K-L, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, et al. Pathogenic Germline
 Variants in 10,389 Adult Cancers. Cell. 2018;173:355-370.e14.
- Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J, et
 al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2
 Mutation Carriers. JAMA. 2017;317:2402–16.
- Ferreira EN, Brianese RC, de Almeida RVB, Drummond RD, de Souza JE, da Silva IT, et
 al. Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple Negative Breast Cancer. Transl Oncol. 2019;12:1453–60.
- Eisinger F, Jacquemier J, Charpin C, Stoppa-Lyonnet D, Bressac-de Paillerets B, Peyrat
 JP, et al. Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res.
 1998;58:1588–92.
- Phillips KA. Immunophenotypic and pathologic differences between BRCA1 and BRCA2
 hereditary breast cancers. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18:107S-12S.
- Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al.
 Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers:
 results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer
 Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol.
 2012;21:134–47.
- 10. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, et al.
 The pathology of familial breast cancer: predictive value of immunohistochemical
 markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with
 mutations in BRCA1 and BRCA2. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20:2310–
 8.
- Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, et al. Distinct
 molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation
 carriers: a population-based study. Cancer Res. 1999;59:2011–7.
- Palacios J, Honrado E, Osorio A, Cazorla A, Sarrió D, Barroso A, et al. Phenotypic
 characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with
 37 immunohistochemical markers. Breast Cancer Res Treat. 2005;90:5–14.

1 13. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, et al. 2 Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and 3 basal phenotype. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11:5175-80. 4 14. Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative 5 breast cancer-the road to new treatment strategies. Lancet Lond Engl. 2017;389:2430–42. 6 15. Mancini P, Angeloni A, Risi E, Orsi E, Mezi S. Standard of Care and Promising New 7 Agents for Triple Negative Metastatic Breast Cancer. Cancers. 2014;6:2187–223. 8 16. Godet I, Gilkes DM. BRCA1 and BRCA2 mutations and treatment strategies for breast 9 cancer. Integr Cancer Sci Ther [Internet]. 2017 [cited 2019 Dec 17];4. Available from: 10 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505673/ 17. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, et al. 11 12 Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast 13 Cancers After Neoadjuvant Chemotherapy. J Clin Oncol. 2009;28:375-9. 14 18. Wunderle M, Gass P, Häberle L, Flesch VM, Rauh C, Bani MR, et al. BRCA mutations 15 and their influence on pathological complete response and prognosis in a clinical cohort 16 of neoadjuvantly treated breast cancer patients. Breast Cancer Res Treat. 2018;171:85–94. 17 19. Sella T, Gal Yam EN, Levanon K, Rotenberg TS, Gadot M, Kuchuk I, et al. Evaluation of 18 tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and 19 taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort. Breast 20 Edinb Scotl. 2018:40:141-6. 21 20. Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S, et al. Tumor-22 infiltrating lymphocytes in patients with HER2-positive breast cancer treated with 23 neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-24 analysis of randomized controlled trials. Cancer Treat Rev. 2017;57:8-15. 25 21. Solinas C, Carbognin L, De Silva P, Criscitiello C, Lambertini M. Tumor-infiltrating 26 lymphocytes in breast cancer according to tumor subtype: Current state of the art. Breast 27 Edinb Scotl. 2017;35:142-50. 28 22. [Recommendations for the immunohistochemistry of the hormonal receptors on paraffin 29 sections in breast cancer. Update 1999. Group for Evaluation of Prognostic Factors using 30 Immunohistochemistry in Breast Cancer (GEFPICS-FNCLCC)]. Ann Pathol. 31 1999;19:336-43. 32 23. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The 33 evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by 34 an International TILs Working Group 2014. Ann Oncol Off J Eur Soc Med Oncol. 35 2015;26:259-71. 24. Dieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca 36 37 F, et al. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including 38 recommendations to assess TILs in residual disease after neoadjuvant therapy and in 39 carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working 40 Group on Breast Cancer. Semin Cancer Biol. 2018;52:16-25.

- Sønderstrup IMH, Jensen MB, Ejlertsen B, Eriksen JO, Gerdes AM, Kruse TA, et al.
 Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCAmutated breast cancer. Acta Oncol Stockh Swed. 2019;58:363–70.
- 4 26. Solinas C, Marcoux D, Garaud S, Vitória JR, Van den Eynden G, de Wind A, et al.
 5 BRCA gene mutations do not shape the extent and organization of tumor infiltrating
 6 lymphocytes in triple negative breast cancer. Cancer Lett. 2019;450:88–97.
- 7 27. Telli ML, Chu C, Badve SS, Vinayak S, Silver DP, Isakoff SJ, et al. Association of
 8 Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and
 9 BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled
 10 Analysis. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;
- 28. Chappuis P, Goffin J, Wong N, Perret C, Ghadirian P, Tonin P, et al. A significant
 response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet.
 2002;39:608–10.
- Byrski T, Huzarski T, Dent R, Marczyk E, Jasiowka M, Gronwald J, et al. Pathologic
 complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients.
 Breast Cancer Res Treat. 2014;147:401–5.
- 30. Byrski T, Huzarski T, Dent R, Marczyk E, Jasiowka M, Gronwald J, et al. Pathological
 complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients.
 Hered Cancer Clin Pract. 2015;13:A8.
- 31. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, et al.
 Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation
 Carriers and Noncarriers: A Single-Institution Experience. J Clin Oncol. 2011;29:3739–
 46.
- 32. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et al. Efficacy of
 neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol Off J Am Soc Clin
 Oncol. 2010;28:1145–53.
- 33. Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, et al.
 Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary
 cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and
 screening[†]. Ann Oncol. 2016;27:v103–10.
- 34. Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, et al. Germline
 Mutation Status, Pathological Complete Response, and Disease-Free Survival in TripleNegative Breast Cancer. JAMA Oncol. 2017;3:1378–85.
- 35. Sæther NH, Skuja E, Irmejs A, Maksimenko J, Miklasevics E, Purkalne G, et al.
 Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a
 retrospective cohort analysis and literature review. Hered Cancer Clin Pract [Internet].
 2018 [cited 2019 Oct 27];16. Available from:
- 38 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924493/
- 36. Ali HR, Dariush A, Provenzano E, Bardwell H, Abraham JE, Iddawela M, et al.
 Computational pathology of pre-treatment biopsies identifies lymphocyte density as a

- predictor of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res
 BCR. 2016;18:21.
- 37. Ali HR, Dariush A, Thomas J, Provenzano E, Dunn J, Hiller L, et al. Lymphocyte density
 determined by computational pathology validated as a predictor of response to
 neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial. Ann
 Oncol Off J Eur Soc Med Oncol. 2017;28:1832–5.
- 38. Hamy A-S, Bonsang-Kitzis H, De Croze D, Laas E, Darrigues L, Topciu L, et al.
 Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after
 Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Clin
 Cancer Res Off J Am Assoc Cancer Res. 2019;25:6731–41.
- 39. Yadav S, Ladkany R, Yadav D, Alhalabi O, Khaddam S, Isaac D, et al. Impact of BRCA
 Mutation Status on Survival of Women With Triple-negative Breast Cancer. Clin Breast
 Cancer. 2018;18:e1229–35.
- 40. Xie Y, Gou Q, Wang Q, Zhong X, Zheng H. The role of BRCA status on prognosis in patients with triple-negative breast cancer. Oncotarget. 2017;8:87151–62.
- 41. Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, et
 al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a
 prospective cohort study. Lancet Oncol. 2018;19:169–80.
- 42. Brekelmans CTM, Tilanus-Linthorst MMA, Seynaeve C, vd Ouweland A, MenkePluymers MBE, Bartels CCM, et al. Tumour characteristics, survival and prognostic
 factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as
 compared to sporadic breast cancer cases. Eur J Cancer Oxf Engl 1990. 2007;43:867–76.
- 43. Templeton AJ, Gonzalez LD, Vera-Badillo FE, Tibau A, Goldstein R, Šeruga B, et al.
 Interaction between Hormonal Receptor Status, Age and Survival in Patients with
 BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression. PloS One.
 2016;11:e0154789.
- 44. Riaz N, Blecua P, Lim RS, Shen R, Higginson DS, Weinhold N, et al. Pan-cancer analysis
 of bi-allelic alterations in homologous recombination DNA repair genes. Nat Commun.
 2017;8:857.
- 45. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early
 breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup[†]. Ann Oncol Off J Eur Soc Med Oncol. 2019;30:1194–220.

Supplementary material

1. Patients and treatments

1.1. Patients

In total, patients with T1-3NxM0 invasive breast cancer (BC) (NEOREP Cohort, CNIL declaration number 1547270) treated at Institut Curie (Paris and Saint Cloud) between 2002 and 2012 were included in this study. We included unilateral, non-recurrent, non-inflammatory, non-metastatic tumors, excluding T4 tumors. NAC regimens changed over time (anthracycline-based regimen or sequential anthracycline-taxane regimen) with trastuzumab used in an adjuvant and/or neoadjuvant setting since 2005 for *HER2*-positive tumors. All patients underwent radiotherapy. Endocrine therapy (tamoxifen or aromatase inhibitor) was prescribed when indicated. This study was approved by the Breast Cancer Study Group of Institut Curie.

1.2. Treatments

NAC regimens changed over time (anthracycline-based regimen or sequential anthracyclinetaxane regimen), with trastuzumab used in an adjuvant and/or neoadjuvant setting for HER2positive tumors since the middle of the past decade. Trastuzumab treatments changer over time due to a change of marketing authorization during the study period. Adjuvant hormone therapy (tamoxifen, aromatase inhibitor, or GnRH agonist) was prescribed when indicated. Surgery (breast-conserving or mastectomy) was performed 4-6 weeks after NAC. Every patient received adjuvant radiotherapy. Adjuvant chemotherapy (ADJ) was decided after multidisciplinary consultation meeting considering patient characteristic, prognosis factor and response to NAC (residual disease and/or node involvement). Patient follow-up after treatment was of every 4 months during the first 2 years, then every 6 months for 3 years, and once a year starting from the 5th year. Follow-up consisted of clinical examination associated to mammography and mammary ultrasound once a year, with annual Magnetic resonance imaging (RMI) in *BRCA*-carriers.

2. Tumor samples and pathological review

2.1. ER, PR, HER2 status and BC subtype

Cases were considered to be estrogen receptor (ER)-positive or progesterone receptor (PR)positive if at least 10% of the tumor cells expressed estrogen and/or progesterone receptors (ER/PR). *HER2* expression was determined by immunohistochemistry, with scoring according to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines (1). Scores of 3+ were reported as positive, and scores of 1+/0 as negative. Tumors with scores of 2+ were further tested by fluorescence *in situ* hybridization (FISH). For *HER2* gene amplification, we evaluated a mean of 40 tumor cells per sample and calculated the mean *HER2* signal per nucleus. A *HER2*/CEN17 ratio \geq 2 was considered positive, and a ratio < 2 was considered negative (1).

2.2. Other pathological parameters

Histological grade was determined as described by Elston Ellis. Mitotic cells were counted on 10 high-power fields (HPF) (x40 objective; field diameter = 0.62 mm) and cutoffs of <11, 12–22 and >22 mitoses were used to define low, intermediate and high mitotic indices, respectively, according to the international recommendations(2). Due to significant differences in distribution before and after NAC, invasive tumor cellularity was binned according to the median value (pre-NAC: 60%; post-NAC: 30%).

2.3 BRCA status

Since 2002, patient referral for genetic counseling depends on individual or family criteria. These criteria are based on the probability of identifying a genetic predisposition in the family of at least 10% (in particular a germline *BRCA1* or *BRCA 2* pathogenic variant). The individual criteria are: early age at diagnosis (under 40) or bilateral breast cancer: synchronous or metachronous (with the first breast cancer before age 50), or specific phenotype (triple negative cancer before age 51). The family criteria are: 3 cases of breast cancer in the same branch of heredity, or 2 cases of breast cancer including 1 under 45-50, of breast or ovarian cancer, or 2 cases of breast cancer including 1 male. The 2 cases are women relatives of the first degree (or second degree if paternal transmission).

2.4 TILs levels

Infiltrates were scored on a continuous scale, as the mean percentage of the stromal area occupied by mononuclear cells. After NAC, we assessed TIL levels within the borders of the residual tumor bed, as defined by the RCB index(3). Nothing is known about the clinical, biological and prognostic significance of TILs in the area of regression in cases of pathological response, but the TILs international working group recently called for their evaluation for research purposes. In cases of pCR, the scar area was measured on macroscopic examination. The scar appeared as a white area in the breast parenchyma corresponding to the tumor bed modified by NAC. It was characterized by the presence of histiocytes, lymphocytes, macrophages, fibrosis and elastosis. The whole fibro-inflammatory scar was evaluated on HE sections (size in mm and stromal TIL level evaluation).

References

- 1. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.
- WHO Classification of Tumours of the Breast. Fourth Edition WHO OMS [Internet]. [cited 2018 Feb 9]. Available from: http://apps.who.int/bookorders/WHP/detart1.jsp?sesslan=1&codlan=1&codcol=70&codc ch=4004
- 3. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25:4414–22.

Supplementary Tables

Supplementary Table S1. BRCA screened patients' characteristics among by BRCA status										
Characteristics	Class	Overall	BRCA mutation	BRCA wild-type	n					
n=		267 (100%)	46(17%)	221(83%)	μ					
Age (mean)		41.31	39.5	41.7	0.15					
Menopausal	pre	228 (85.7%)	41 (89. 1%)	187 (85.0%)	0.62					
status	post	38 (14.3%)	5 (10. 9%)	33 (15.0%)						
BMI (mean)		23.50	22.8	23.6	0.24					
BMI dass	[15,19]	23 (8.6%)	6 (13. 3%)	17 (7.7%)	0.248					
	(19,25]	178 (66.9%)	31 (68.9%)	147 (66.5%)						
	(25,30]	47 (17.7%)	4 (8.9%)	43 (19.5%)						
	(30,50]	18 (6.8%)	4 (8.9%)	14 (6.3%)						
Family history	no	116 (43.9%)	12 (26.1%)	104 (47.7%)	0.01					
of B C	yes	148 (56.1%)	34 (73.9%)	114 (52.3%)						
Clinical tumor size	T1	27 (10.1%)	5 (10. 9%)	22 (10.0%)	0.50					
	Т2	181 (67.8%)	28 (60.9%)	153 (69.2%)						
	Т3	59 (22.1%)	13 (28.3%)	46 (20.8%)						
Clinical	NO	110 (41.2%)	17 (37.0%)	93 (42.1%)	0.63					
nodal status	N1-N2-N3	157 (58.8%)	29 (63.0 %)	128 (57.9%)						
Histology	NST	256 (95.9%)	43 (93.5%)	213 (96.4%)	NaN					
	others	11 (4. 1%)	3 (6.5%)	8 (3.6%)						
Grade	-	86 (32.8%)	10 (23.3%)	76 (34.7%)	0.24					
		176 (67.2%)	33 (76.7%)	143 (65.3%)						
Mitotic Index (mean)	26.57	30.8	25.6	0.24					
Subtype	luminal	90 (33.7%)	15 (32.6%)	75 (33.9%)	<0.01					
	TNBC	110 (41.2%)	27 (58.7%)	83 (37.6%)						
	HER2	67 (25.1%)	4 (8.7%)	63 (28.5%)						
str TILs (mean)		20.0 [10.0-40.0]	20.0[13.8-40.0]	20.0 [10.0-40.0]	0,78					
IT TILs (mean)		5.0 [5.0-15.0]	5.0[5.0-11.3]	7.5 [5.0-20.0]	0,72					
NAC Regimen	AC	29 (10.9%)	4 (8.7%)	25 (11.4%)	0.49					
	AC-Taxanes	221 (83.1%)	41 (89. 1%)	180 (81.8%)						
	Taxanes	7 (2.6%)	1 (2.2%)	6 (2.7%)						
	Others	9 (3.4%)	0 (0.0%)	9 (4. 1%)						
pCR class	No pCR	182 (68.4%)	25 (54.3%)	157 (71.4%)	0,04					
	pCR	84 (31.6%)	21 (45.7%)	63 (28.6%)						
Nodal involvment	0	176 (66.2%)	35 (76.1%)	141 (64.1%)	0,16					
	1-3	64 (24.1%)	6 (13.0%)	58 (26.4%)						
	≥4	26 (9.8%)	5 (10. 9%)	21(9.5%)						
str TILs (mean)		10.0 [5.0-15.0]	15.0 [5.0-20.0]	10.0 [5.0-15.0]	0,14					
IT TILs (mean)		5.0 [2.0-10.0]	5.0 [4.3-10.0]	5.0[2.0-10.0]	0,27					

Missing data: Menopausal status, n=1; BMI (continuous), n=1; BMI class, n=1; Family history, n=3; Grade, n=5; Mitotic index, n=77; Pre-NAC str TILs, n=75; Pre-NAC IT TILs, n=75; NAC regimen, n=1; pCR status, n=1; Post-NAC Nodal involvment, n=1; Post-NAC str TILs, n=75; Post-NAC IT TILS, n=147.

NAC=neoadjuvant chemotherapy ; BMI=body mass index; NST= no special type ; TNBC= triple negative breast cancer ; str TILs= stromal tumor-infiltrating lymphocytes ; IT TILs= intratumoral-infiltrating lymphocytes; AC=anthracyclines; pCR=Pathologic complete response.

The "n" denotes the number of patients. In case of categorical variables, percentages are expressed between brackets. In case of continuous variables, mean value is reported. In case of nonnormal continuous variables, median value is reported, with interquartile range between brackets.

Supplementary Ta	ble S 2 . Patients´ch	haracteristics in each	n tumor subty pe and	d by BRCA status								
	Luminal					TNBC			HER 2			
Characteristics	Class	BRCA mutation	BRCA wild-type		BRCA mutation	BRCA wild-type	-	BRCA mutation	BRCA wild-type			
n=	-	15 (16.7%)	75 (83.3%)	p p	27 (24.5%)	83 (75.5%)	ρ	4 (6.0%)	63 (94.0%)	ρ		
Age (mean)		38.5	42.3	0,13	39.6	42.2	0,19	43.5	40.2	0,50		
Menopausal	pre	14 (93.3%)	64 (86.5%)	0,76	24 (88.9%)	72 (86.7%)	1,00	3 (75.0%)	51 (81.0%)	1,00		
sta tus	post	1 (6.7%)	10 (13.5%)		3 (11.1%)	11 (13.3%)		1 (25.0%)	12 (19.0%)			
BMI (mean)		22.2	23.5	0,32	23.5	23.3	0,74	20.4	24.3 (4.4%)	0,09		
BMI class	[15,19]	4 (28.6%)	7 (9.3%)	0.204	1 (3.7%)	7 (8.4%)	0.251	1 (25.0%)	3 (4.8%)	0.298		
	(19,25]	8 (57.1%)	49 (65.3%)		20 (74.1%)	55 (66.3%)		3 (75.0%)	43 (68.3%)			
	(25,30]	1 (7.1%)	14 (18.7%)		3 (11.1%)	18 (21.7%)		0 (0.0%)	11 (17.5%)			
	(30,50]	1 (7.1%)	5 (6.7%)		3 (11.1%)	3 (3.6%)		0 (0.0%)	6 (9.5%)			
Family history	no	2 (1 3.3%)	26 (35.1%)	0,18	10(37.0%)	46 (56.1%)	0,13	0 (0.0%)	32 (51.6%)	0,14		
	yes	13 (86.7%)	48 (64.9%)		17(63.0%)	36 (43.9%)		4 (100.0%)	30 (48.4%)			
Clinical tumor size	Т1	1 (6.7%)	5 (6.7%)	0,99	2 (7.4%)	11 (13.3%)	0,28	2 (50.0%)	6 (9.5%)	0,04		
	Т2	11 (73.3%)	54 (72.0%)		16(59.3%)	56 (67.5%)		1 (25.0%)	43 (68.3%)			
	тз	3 (20.0%)	16 (21.3%)		9 (33.3%)	16 (19.3%)		1 (25.0%)	14 (22.2%)			
Clinical	NO	5 (33.3%)	35 (46.7%)	0,51	10(37.0%)	34 (41.0%)	0,89	2 (50.0%)	24 (38.1%)	1,00		
nodal status	N1-N2-N3	10 (66.7%)	40 (53.3%)		17(63.0%)	49 (59.0%)		2 (50.0%)	39 (61.9%)			
Histology	NST	13 (86.7%)	72 (96.0%)	NaN	26 (96.3%)	78 (94.0%)	NaN	4 (100.0%)	63 (100.0%)	NaN		
	others	2 (13.3%)	3 (4.0%)		1 (3.7%)	5 (6.0%)		0 (0.0%)	0 (0.0%)			
Grade	-	6 (42.9%)	42 (56.0%)	0,55	2 (8.0%)	10 (12.2%)	0,53	2 (50.0%)	24 (38.7%)	NaN		
	111	8 (57.1%)	33 (44.0%)		23(92.0%)	72 (87.8%)		2 (50.0%)	38 (61.3%)			
Mitotic Index (mea	n)	23.0	18.5	0,56	36.3	31.8	0,46	13.0	21.5	0,45		
str TILs (mean)		12.5 [8.8-15.0]	15.0 [10.0-25.0]	0,17	27.5 [15.0-60.0]	30.0 [15.0-50.0]	0,71	22.5 [20.0-28.8]	20.0 [10.0-35.0]	0,66		
IT TILs (mean)		5.0 [4.3-6.3]	10.0 [5.0-15.0]	0,07	5.0 [5.0-15.0]	5.0 [2.0-15.0]	0,37	15.0 [10.0-20.0]	15.0 [5.0-20.0]	0,77		
NAC Regimen	AC	3 (20.0%)	13 (17.6%)	0,83	1 (3.7%)	9 (10.8%)	NaN	0 (0.0%)	3 (4.8%)	0,77		
	AC-Taxanes	11 (73.3%)	58 (78.4%)		26 (96.3%)	73 (88.0%)		4 (100.0%)	49 (77.8%)			
	Taxanes	1 (6.7%)	2 (2.7%)		0 (0.0%)	0 (0.0%)		0 (0.0%)	4 (6.3%)			
	Others	0 (0.0%)	1 (1.4%)		0 (0.0%)	1 (1.2%)		0 (0.0%)	7 (11.1%)			
pCR class	No pCR	10 (66.7%)	70 (94.6%)	<0,01	14 (51.9%)	47 (56.6%)	0,83	1 (25.0%)	40 (63.5%)	0,32		
	pCR	5 (33.3%)	4 (5.4%)		13(48.1%)	36 (43.4%)		3 (75.0%)	23 (36.5%)			
Nodalinvolument	0	8 (53.3%)	30 (40.5%)	0,23	23 (85.2%)	65 (78.3%)	0,74	4 (100.0%)	46 (73.0%)	0,49		
Nodarmvolvment	1-3	3 (20.0%)	32 (43.2%)		3 (11.1%)	13 (15.7%)		0 (0.0%)	13 (20.6%)			
	≥4	4 (26.7%)	12 (16.2%)		1 (3.7%)	5 (6.0%)		0 (0.0%)	4 (6.3%)			
str TILs (mean)		15.0 [13.8-20.0]	10.0 [5.0-10.0]	<0,01	10.0 [5.0-20.0]	10.0 [5.0-25.0]	0,82	10.0 [4.3-15.0]	10.0 [5.0-12.5]	0,95		
IT TILs (mean)		10.0 [5.0-12.5]	5.0 [3.0-5.0]	0,02	5.0[1.8-6.3]	5.0 [3.0-10.0]	0,54	5.0 [5.0-5.0]	5.0 [2.0-5.0]	0,68		

Missing data: Menopausal status, n=1; BMI (continuous), n=1; BMI class, n=1; Family history, n=3; Grade, n=5; Mitotic index, n=77; Pre-NAC str TiLs, n=75; Pre-NAC IT TiLs, n=75; NAC regimen, n=1; pCR status, n=1; Post-NAC Nodal involvment, n=1; Post-NAC str TiLs, n=75; Post-NAC IT TILS, n=147.

NAC=neoadjuvant chemotherapy; BMI = body mass index; NST = no special type; TNBC = triple negative breast cancer; str TILs = stromal tumor-infiltrating lymphocytes; IT TILs = intratumoral-infiltrating lymphocytes; AC = anthracyclines; pCR = Pathologic complete response.

The "n" denotes the number of patients. In case of categorical variables, percentages are expressed between brack ets. In case of continuous variables, mean value is reported. In case of nonnormal continuous variables, median value is reported, with interquartile range between brack ets.

Supplementary Table S3. Association of BRCA status with pCR after univariate and multivariate analysis in the whole population

					Univariate			Multivariate			
			Nbin								
Variable	Class	N b total	model	Events	HR	CI	RCH	р	HR	CI	р
Pre-NAC parameters											
Age (years)											
Menopausal status	pre	227	227	70	1		30.8%				
	post	38	38	14	1.31	[0.63 - 2.65]	36.8%	0,46			
BMI class	≤19	23	23	8	1		34.8%				
	19-25	177	177	56	0.87	[0.36 - 2.27]	31.6%	0,76			
	25-30	47	47	17	1.06	[0.38-3.11]	36.2%	0,90			
	>30	18	18	3	0.37	[0.07 - 1.58]	16.7%	0,20			
BRCA status	BRCA mutation	46	46	21	1		45.7%				
	BRCA wild-type	220	220	63	0.48	[0.25 - 0.92]	28.6%	0,03			
Tumor size	T1	27	27	15	1		55.6%				
	Τ2	181	181	57	0.37	[0.16 - 0.83]	31.5%	0,02	0.51	[0.17 - 1.49]	0.22
	Т3	58	58	12	0.21	[0.08 - 0.55]	20.7%	<0.01	0.26	[0.07 - 0.89]	0.03
Clinical nodal status	NO	110	110	33	1		30%				
	N1	145	145	48	1.15	[0.68 - 1.98]	33.1 %	0,61			
	N2	8	8	2	0.78	[0.11 - 3.58]	25%	0,77			
	N3	3	3	1	1.17	[0.05 - 12.59]	33.3%	0,91			
Grade	I	7	7	1	1		14.3%				
	Ш	78	78	17	1.67	[0.26 - 32.72]	21.8%	0,65			
		176	176	66	3.6	[0.6 - 68.78]	37.5%	0.24			
Mitotic index	≤22	101	101	29	1		28.7%				
	>22	88	88	34	1.56	[0.85 - 2.89]	38.6%	0.15	0.89	[0.42 - 1.83]	0.74
BC subtype	luminal	89	89	9	1		10.1 %				
	TNBC	110	110	49	7.14	[3.39 - 16.57]	44.5%	<0.01	8.6	[2.76 - 33.41]	<0.01
	HER2	67	67	26	5.64	[2.5 - 13.78]	38.8%	<0.01	6.31	[1.99 - 24.48]	<0.01
str TILs (%)				84	1.03	[1.02 - 1.05]		<0.01	1.01	[0.99 - 1.04]	0.33
IT TILs (%)				84	1.04	[1.02 - 1.07]		<0.01	1.03	[0.98 - 1.07]	0.24
NAC regimen	AC	29	29	7	1		24.1 %				
	AC-Taxan es	221	221	72	1.52	[0.65 - 3.99]	32.6%	0,36			
	Taxanes	7	7	3	2.36	[0.39-13.48]	42.9%	0,33			
	Others	9	9	2	0.9	[0.12-4.86]	22.2%	0,91			

Abbreviation, BMI=body mass index; ER=oestrogen receptor; PR=progesterone receptor; TNBC= triple negative breast cancer; str TILs= stromal tumor-infiltrating lymphocytes; IT TILs= intratumoral-infiltrating lymphocytes; NAC=neoadjuvant chemotherapy; AC=anthracy clines; pCR=Pathologic complete response.

Supplementary Figures



Supplementary Figure S 1. Study flow diagram of included patients and tumors samples available



Supplementary Figure S 2. Patients' and tumors 'characteristics by BRCA status. (All(n=1199), BRCA mutation (n=36), BRCA wild-type(n=156), not screened (n=1007). A, Age (kernel density plot). B, BMI (kernel density plot). C, Menopausal status (barplot). D, Family history (barplot). E, Clinical tumor stage (barplot). F, Clinical nodal status (barplot). G, Histology (barplot). H, Grade (barplot). I, BC subtype (barplot).



Supplementary Figure S 3. Variation of pre-NAC str TIL levels according to the pre-NAC IT TIL levels (scatterplot) (str TILs (n=192), IT TILs (n=192)).





BC patients with pre-NAC str TIL levels available and pCR, by deciles [n=191; Luminal (n= 51), TNBC (n= 97) and HER2-positive (n= 43)

Supplementary Figure S 4. pCR rate by pre-NAC str TiL levels by BRCA status (TiLs were binned by increments of 10%). A, whole population (n=191, BRCA mutation (n=36), BRCA wild-type(n=155)). B, luminal tumors (n=51, BRCA mutation(n=8), BRCA wild-type(n=43)). C, TNBC (n=97), BRCA mutation(n=24), BRCA wild-type(n=73)). D, HER2-positive BC (n=43, BRCA mutation(n=4), BRCA wild-type(n=39)).



Supplementary Figure S 5. TILs correlation between pre and post-NAC. A, Variation of post-NAC str TIL levels according to the pre-NAC str TIL levels (scatterplot) (pre-NAC str TILs (n=192), post-NAC str TILs (n=192)). B, Variation of post-NAC IT TIL levels according to the pre-NAC IT TIL levels (scatterplot) (pre-NAC IT TILs (n=192), post-NAC IT TILs (n=120)).



Supplementary Figure S 6. Relapse free survival curves according BRCA status. A, whole population (n=267, BRCA mutation (n=46), BRCA wild-type(n=220)). B, luminal tumors (n=89, BRCA mutation(n=15), BRCA wild-type(n=74)). C, TNBC (n=110, BRCA mutation(n=27), BRCA wild-type(n=83)). D, HER2-positive BC (n=67), BRCA mutation(n=4), BRCA wild-type(n=63)).



 $\begin{array}{l} \textbf{Supplementary Figure S 7} & . \\ \textbf{Overall survival curves according BRCA status. A, whole population (n=267, BRCA mutation (n=46), BRCA wild-type(n=220)). \\ \textbf{B}, luminal tumors (n=89, BRCA mutation(n=15), BRCA wild-type(n=74)). \\ \textbf{C}, TNBC (n=110, BRCA mutation(n=27), BRCA wild-type(n=83)). \\ \textbf{D}, HER2-positive BC (n=67), BRCA mutation(n=4), BRCA wild-type(n=63)). \\ \end{array}$